Clinical Trial Update: BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) [Phase 3]

View source ↗

Summary

Phase 3 trial (LUX-LUNG 1) evaluated afatinib (BIBW 2992) plus best supportive care versus placebo in non-small cell lung cancer patients who progressed after e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2013-11-27